| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.3 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | -0.18 | 0.3 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.06 | 0.3 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.3 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |